HONG KONG – Scandals continue to cast a shadow on China's vaccine industry, with Changchun Changsheng Life Sciences Ltd. recently handed a hefty fine totaling ¥9.1 billion (US$1.3 billion). Meanwhile another vaccine maker, Sinovac Biotech Ltd., has been hobbled by company infighting, which has forced it to suspend production of vaccines for hepatitis A and seasonal flu, markets for which it supplied 18 percent and 12.7 percent, respectively, of vaccine production in China last year. Read More
HONG KONG – China biopharmaceutical firm Zai Lab Ltd. bagged marketing approval from Hong Kong's Department of Health this week for its PARP inhibitor, Zejula (niraparib), targeting patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian cancer. It is intended for second-line maintenance use for adult ovarian cancer patients. Read More
HONG KONG – Antibody specialist Hifibio Therapeutics Inc. has picked up French immuno-oncology company H-Immune Therapeutics SAS in a deal that adds pipeline programs, a platform technology and expertise in an increasingly competitive field. Read More
PERTH, Australia – Australia is kicking off its first-ever registry-based randomized controlled trials in oncology to help clinicians select the right treatments for the right patients. Read More
The most comprehensive analysis of the largest functional genomic dataset of primary acute myeloid leukemia (AML) tumor biopsies to date has revealed important new information about biology and potential translational approaches that could translate into new clinical treatment approaches. Read More
HONG KONG – Biotech company Maz World Ltd. is working with the Institute of Molecular and Cell Biology of Singapore's Agency for Science, Technology and Research (IMCB A*STAR) to use its ostrich antibody technology to neutralize the four serotypes of dengue viruses. Read More
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, disclosed its decision to invest ¥700 million (US$6.2 million) in Meltin MMI, of Tokyo. At the same time, the two companies signed a joint research and development agreement. Meltin aims to enhance the functionality of cyborg technologies and the combination of bio-signal processing and robotics. than pharmaceuticals as "frontier areas," with the aim of exploring new business opportunities. Read More
